# Monopteros Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/monopteros-therapeutics

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.monopterostx.com
- Total disclosed funding: $20M
- Latest round: Series A (Apr 22, 2021)
- Investors on record: 1

## About

Based in Massachusetts, US, and founded in 2019, Monopteros Therapeutics Inc. operates as a pharmaceutical research company that reprograms regulatory T cells (“Tregs”) for cancer immunotherapy resistance. The company was co-founded by Thorsten Mempel, MD, Ph.D., and Ulrich von Andrian, MD. In 2021, the company raised USD 20 million in series A funding from Medicxi.

Monopteros Therapeutics Inc.'s research team develops MPT-0118 that undergo a dose escalation and cohort expansion clinical trial. The MPT-0118 is provided as a tablet formulation for oral dosing in its Phase 1/1b clinical trial.

## Funding rounds

- Series A, Apr 22, 2021, $20M — Medicxi

## Investors

- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series A